Keros Therapeutics, Inc. 8K

Keros Therapeutics’ board authorized a $5 million share repurchase program funded by a $20 million milestone payment from Takeda tied to elritercept’s ELRiSE MDS trial.

On September 8, 2026, Keros Therapeutics, Inc. announced that its Board of Directors has authorized a $5 million share repurchase program for the company’s common stock, to be funded following receipt of a $20 million development milestone payment from Takeda Pharmaceuticals U.S.A., Inc. under their elritercept license agreement after first patient dosing in the ELRiSE MDS clinical trial; the authorization permits management to repurchase shares from time to time in the open market or by other means, subject to market conditions, legal and contractual constraints, and may be modified, suspended, or discontinued at any time without obligating the company to repurchase any specific amount.

Filing Facts

CIK

1664710

Ticker

-

Form

8K

Source Type

sec

Accession

0001664710-26-000053

Alert Tier

6